Extended-Spectrum Antibiotics No Benefit for Pediatric Appendicitis

Share this content:
Extended-Spectrum Antibiotics No Benefit for Pediatric Appendicitis
Extended-Spectrum Antibiotics No Benefit for Pediatric Appendicitis

FRIDAY, July 1, 2016 (HealthDay News) -- For children diagnosed with appendicitis undergoing appendectomy, extended-spectrum antibiotics seem to offer no advantage over narrower-spectrum agents, according to a study published online June 28 in Pediatrics.

Matthew P. Kronman, M.D., from the University of Washington in Seattle, and colleagues performed a retrospective cohort study involving children aged 3 to 18 years discharged between 2011 and 2013 with an appendicitis diagnosis and appendectomy performed. Data were included for 24,984 patients.

The researchers found that 70.7 percent of the patients had uncomplicated appendicitis and 29.3 percent had complicated appendicitis (postoperative length of stay of three or more days, central venous catheter placed, major or severe illness classification, or intensive care unit admission). Overall, 2.7 percent of patients experienced the primary outcome of 30-day readmission for wound infection or repeat abdominal surgery (1.1 and 6.4 percent, respectively, among uncomplicated and complicated cases [P < 0.001]). There was a significant correlation for extended-spectrum antibiotic exposure with the primary outcome in complicated (adjusted odds ratio, 1.43; 95 percent confidence interval, 1.06 to 1.93) but not uncomplicated (adjusted odds ratio, 1.32; 95 percent confidence interval, 0.88 to 1.98) appendicitis.

"Extended-spectrum antibiotics seem to offer no advantage over narrower-spectrum agents for children with surgically managed acute uncomplicated or complicated appendicitis," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »